Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news


From To
Japan: Hepatitis C drug fakes found in Nara drugstore chain

Counterfeits of the hepatitis C drug Harvoni have been found at a drugstore chain in Nara Prefecture, the health ministry said Tuesday. Harvoni is sold by a Japanese unit of U.S. pharmaceutical firm Gilead Sciences Inc. The ingredients of the counterfeits are now under examination.

18 January 2017
The Japan Times
The U.S. Government Should Buy Gilead For $156 Billion To Save Money On Hepatitis C

The U.S. government could cure most Americans suffering from hepatitis C infections if it simply bought drug maker Gilead Sciences on the stock market rather than purchasing its products in the drug market.

17 January 2017
Access to highly effective hepatitis C treatment in Portugal: A Community Perspective

This document presents a case study of community engagement for highly effective hepatitis C treatment, led by the Grupo de Ativistas em Tratamentos. It demonstrates the process of price and reimbursement negotiations in Portugal and lessons learned in advocacy for universal (or as close as possible) access to these and other life-saving drugs.

19 December 2016
Gilead’s Patent Loss to Merck Started With a Broken Friendship

Jury may have been swayed by ‘story of betrayal,’ lawyers say. Gilead will use law, not emotion, to seek to overturn verdict.

19 December 2016
Hepatitis C patients 'go abroad for drugs'

Charities and liver specialists are warning that people with Hepatitis C are buying medications from India, to avoid long waits on the NHS. Radio 4's You & Yours has seen confidential documents, which suggest the cost to the NHS of some medications has dropped by nearly three-quarters, but experts say that NHS England still has not increased the number of patients it will treat.

19 December 2016
BBC Radio 4 (audio)
Merck wins $2.54 billion in hepatitis C drug trial against Gilead

Merck & Co on Thursday was awarded $2.54 billion in royalties by a federal jury in a patent lawsuit against Gilead Sciences Inc over Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni.

16 December 2016
Sofosbuvir-based therapy achieves excellent SVR12 rates among people who inject drugs in Ukraine

People who inject drugs (PWID) can have an excellent response to sofosbuvir-based therapy for hepatitis C virus (HCV) infection, Ukrainian research presented to the recent 2016 AASLD Liver

07 December 2016
Michael Carter
Hepatitis C drugs Australia's most expensive, cost taxpayers $1 billion in four months

Hepatitis C medications approved in March this year have already topped the list of Australia's most expensive drugs, costing the taxpayer $1 billion. The latest figures have outlined 10 most prescribed and most expensive drugs on the Pharmaceutical Benefits Scheme (PBS) in the past year.

05 December 2016
ABC Online
New WHO report shows strategic purchasing of medicines can improve access in the European Region

A new WHO report provides insight into how countries in the WHO European Region can improve access and reduce medicine prices through strategic and well-planned procurement processes. The report examines the effect of different public procurement practices on supply security and prices for pharmaceuticals. It also addresses collaboration within and across countries to improve availability of affordable medicines for patients in the Region.

02 December 2016
World Health Organization
DAA treatment restricted for Canadian hepatitis C patients

Patients infected by hepatitis C virus (HCV) in Canada have limited access to direct-acting antiviral (DAA) agents, according to a new study. For example, 85% to 92% of the provinces and territories in Canada restrict access to these medications to persons with moderate fibrosis.

29 November 2016
Medical Economics
← First12345...86Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.